Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Shandong

Drug and asset intelligence for Shandong with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Recent signals(1)

StrategyJuly 18, 2026

FDA Grants Approval for Brivaracetam ANDA219766 by Shandong

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219766 for Brivaracetam submitted by Shandong.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Shandong

July 18, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Antiepileptic →
Neurology →
Neurology · Antiepileptic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.